Revive Therapeutics Stock Today
| RVVTF Stock | USD 0.01 0.0009 12.86% |
Performance2 of 100
| Odds Of DistressLess than 47
|
Revive Therapeutics is trading at 0.0061 as of the 11th of December 2024. This is a 12.86 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0061. Revive Therapeutics has 47 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 17th of December 2023 and ending today, the 11th of December 2024. Click here to learn more.
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company was incorporated in 2012 and is headquartered in Toronto, Canada. Revive Therapeutics is traded on OTC Exchange in the United States.. The company has 353.56 M outstanding shares. More on Revive Therapeutics
Moving against Revive OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Revive OTC Stock Highlights
| Business Concentration | Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Revive Therapeutics [RVVTF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.1 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Revive Therapeutics's market, we take the total number of its shares issued and multiply it by Revive Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Revive Therapeutics classifies itself under Pharmaceuticals sector and is part of Health Care industry. The entity has 353.56 M outstanding shares.
Revive Therapeutics has accumulated about 5.29 M in cash with (13.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Revive Therapeutics Probability Of Bankruptcy
Ownership AllocationRevive Therapeutics owns a total of 353.56 Million outstanding shares. Roughly 95.1 pct. of Revive Therapeutics outstanding shares are held by general public with 2.48 % owned by insiders and only 2.42 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Revive Ownership Details
Revive Therapeutics Risk Profiles
| Mean Deviation | 7.27 | |||
| Semi Deviation | 8.66 | |||
| Standard Deviation | 11.21 | |||
| Variance | 125.61 |
Revive Stock Against Markets
Picking the right benchmark for Revive Therapeutics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Revive Therapeutics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Revive Therapeutics is critical whether you are bullish or bearish towards Revive Therapeutics at a given time. Please also check how Revive Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Revive Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Revive Therapeutics Corporate Management
Elected by the shareholders, the Revive Therapeutics' board of directors comprises two types of representatives: Revive Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revive. The board's role is to monitor Revive Therapeutics' management team and ensure that shareholders' interests are well served. Revive Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revive Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Frank | Chairman CEO | Profile | |
| Derrick Welsh | COO Pharma | Profile | |
| Onesmo Mpanju | Chief Consultant | Profile | |
| ACIS BComm | Chief Officer | Profile | |
| McKee MD | Chief Consultant | Profile |
Other Information on Investing in Revive OTC Stock
Revive Therapeutics financial ratios help investors to determine whether Revive OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Revive with respect to the benefits of owning Revive Therapeutics security.